%0 Journal Article
%A Bozorgmehr, Farastuk
%A Chung, Inn
%A Fischer, Jürgen R
%A Bischof, Marc
%A Atmaca, Akin
%A Wetzel, Sophie
%A Faehling, Martin
%A Bottke, Dirk
%A Wermke, Martin
%A Troost, Esther G C
%A Kropf-Sanchen, Cornelia
%A Wiegel, Thomas
%A Schmidt, Bernd
%A Stupavsky, Andrej
%A Engel-Riedel, Walburga
%A Hammer-Hellmig, Michaela
%A Reinmuth, Niels
%A Manapov, Farkhad
%A Grohe, Christian
%A Krempien, Robert
%A Schumann, Christian
%A Sterzing, Florian
%A Reck, Martin
%A Würschmidt, Florian
%A Fleckenstein, Jochen
%A Petroff, Alev
%A Henschke, Sven
%A Behnisch, Rouven
%A Cvetkovic, Jelena
%A Brückner, Lena
%A Schwab, Constantin
%A Stenzinger, Albrecht
%A Götze, Thorsten
%A Kopp, Christina
%A Schröder, Helge
%A Debus, Jürgen
%A Christopoulos, Petros
%A Thomas, Michael
%A Rieken, Stefan
%T Reconsidering palliative radiotherapy in addition to PD-1 blockade for non-small cell lung cancer: results from the FORCE phase II trial (AIO/YMO-TRK-0415).
%J Clinical & experimental metastasis
%V 42
%N 5
%@ 0262-0898
%C Dordrecht
%I Springer Science + Business Media B.V.
%M DKFZ-2025-01541
%P 42
%D 2025
%X Introduction of immune checkpoint inhibitors (ICI) has improved overall survival (OS) for advanced non-small cell lung cancer (NSCLC). However, responses differ greatly amongst patients. Additional radiotherapy (RT) may promote tumor-specific immunity and synergize with ICI to improve tumor control. The multicenter phase II FORCE trial evaluated safety and efficacy of nivolumab with additional palliative radiotherapy (5 × 4 Gy) as clinically indicated in pre-treated metastatic non-squamous NSCLC (group A, n = 41), including pretreated patients without an indication for radiotherapy in a parallel cohort as real-world controls (group B, n = 60). With an objective response rate (ORR) of 8.3
%K Humans
%K Carcinoma, Non-Small-Cell Lung: therapy
%K Carcinoma, Non-Small-Cell Lung: pathology
%K Carcinoma, Non-Small-Cell Lung: mortality
%K Carcinoma, Non-Small-Cell Lung: drug therapy
%K Male
%K Female
%K Lung Neoplasms: pathology
%K Lung Neoplasms: therapy
%K Lung Neoplasms: mortality
%K Lung Neoplasms: drug therapy
%K Aged
%K Middle Aged
%K Immune Checkpoint Inhibitors: therapeutic use
%K Palliative Care: methods
%K Nivolumab: therapeutic use
%K Programmed Cell Death 1 Receptor: antagonists & inhibitors
%K Aged, 80 and over
%K Adult
%K Immunotherapy (Other)
%K Nivolumab (Other)
%K Non-small cell lung cancer (Other)
%K Palliative radiotherapy (Other)
%K Radioimmunotherapy (Other)
%K Immune Checkpoint Inhibitors (NLM Chemicals)
%K Nivolumab (NLM Chemicals)
%K Programmed Cell Death 1 Receptor (NLM Chemicals)
%K PDCD1 protein, human (NLM Chemicals)
%F PUB:(DE-HGF)16
%9 Journal Article
%$ pmid:40702361
%2 pmc:PMC12287132
%R 10.1007/s10585-025-10358-x
%U https://inrepo02.dkfz.de/record/303122